Search Results for "Cross Reactivity Of Plavix And Effient"
Original Source: Allergic Reactions to Clopidogrel and Cross-Reactivity to Other Agents.
Clopidogrel is a widely used antiplatelet agent, particularly after coronary stent implantation. About 1% of patients have allergic or hematologic adverse reactions to clopidogrel. This has important therapeutic implications, as premature discontinuation of clopidogrel is the strongest risk factor for stent thrombosis. Clopidogrel allergy most commonly manifests as a rash. It is important to distinguish this from other causes of rash occurring in patients who have had a recent coronary stent. Although antih...
Matching Channels
Plavix is a clot-busting drug, produced by Bristol-Myers Squibb Company, and reached annual sales in 2009 of $4.2m, making the third highest drug in the world (based on 2009 annual sales). Prescri...
Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug
Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It re...
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health...
O2PR is a specialist PR and communications consultancy providing bespoke services to public and private sector organisations operating in the fields of science, engineering and technology. The de...
Food safety is a scientific discipline describing handling, preparation, and storage of food in ways that prevent foodborne illness. This includes a number of routines that should be followed to avo...
Matching News
New Blood Thinner Effient No Better Than Plavix at Preventing Heart Trouble: Study
SUNDAY, Aug. 26 -- The newer blood thinner Effient is no more effective than the widely used Plavix in preventing death, heart attacks or strokes, new research finds. Nor is Effient (prasugrel) any sa...
Latest News From "The Pink Sheet" DAILY - Effient Goes Up Against Plavix Head To Head
Study Shows Effient Not Superior To Plavix, But Bleeding Risk Similar
Study Shows Effient Not Superior To Plavix, But Bleeding Risk Similar
A study published in the New England Journal of Medicine showed Effient was not superior to Plavix in treating patients who had not undergone revascularization.
Antiplatelet Switch Still Has Bleeding Risks (CME/CE)
(MedPage Today) -- Switching high-risk patients to clopidogrel (Plavix) can help counteract the low platelet reactivity common with prasugrel (Effient), but doing so has risks of its own, a first-of-i...
Effient misses Phase III endpoint vs. Plavix
Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) and Eli Lilly and Co. (NYSE:LLY) said Effient prasugrel plus low-dose aspirin missed the composite primary endpoint vs. Plavix clopidogrel plus low-dos...
MIAMI, Oct. 23, 2012 /PRNewswire/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced new results of two retrospective, observational, comparative effectiveness studies...
Lilly heart drug Effient fails to carve new niche
MUNICH (Reuters) - Eli Lilly's new heart drug Effient failed to beat the older product Plavix in a head-to-head clinical study, dashing hopes for its expanded use in treating less critically sick hear...
Lilly's heart drug Effient fails to carve new niche
MUNICH (Reuters) - Eli Lilly's heart drug Effient failed to beat the older product Plavix in a head-to-head clinical study, dealing a blow to hopes for its expanded use in treating less critically sic...
Matching PubMed Articles
An algorithm for use of Prasugrel (Effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention at the Brigham and Women's Hospital is presented. Our algorithm, which...
Cross-reactivity of antibodies in AGRAQUANT, DON EIA, VERATOX, ROSA LF-DONQ, and MYCONTROLDON designed for deoxynivalenol (DON) determination in food and feedstuffs was evaluated against nivalenol, 3-...
Peptide cross-reactivity: the original sin of vaccines.
Recent numerous studies have demonstrated that an extensive peptide identity platform characterizes entities spanning the entire evolutionary arc from viruses to humans and establishes an immune cross...
Evaluation of cross-reactive antibody response to HVR1 in chronic hepatitis C.
AIM: To evaluate the presence and cross-reactive antibodies against hypervariable region 1 (HVR1) in hepatitis C virus (HCV) infected patients and its relationship with the progression of the disease....
Myceliophthora thermophila is a thermophilic mould widely found in the environment but rarely responsible for human infections. We describe a case of invasive Myceliophthora thermophila infection mimi...
